SG11202109383XA - Recombinant bacteria and uses thereof - Google Patents

Recombinant bacteria and uses thereof

Info

Publication number
SG11202109383XA
SG11202109383XA SG11202109383XA SG11202109383XA SG11202109383XA SG 11202109383X A SG11202109383X A SG 11202109383XA SG 11202109383X A SG11202109383X A SG 11202109383XA SG 11202109383X A SG11202109383X A SG 11202109383XA SG 11202109383X A SG11202109383X A SG 11202109383XA
Authority
SG
Singapore
Prior art keywords
recombinant bacteria
recombinant
bacteria
Prior art date
Application number
SG11202109383XA
Inventor
Yongliang Zhang
Chin Wen Png
Original Assignee
Nat Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Singapore filed Critical Nat Univ Singapore
Publication of SG11202109383XA publication Critical patent/SG11202109383XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202109383XA 2019-02-28 2020-02-28 Recombinant bacteria and uses thereof SG11202109383XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201901828TA SG10201901828TA (en) 2019-02-28 2019-02-28 Recombinant bacteria and uses thereof
PCT/SG2020/050095 WO2020176042A1 (en) 2019-02-28 2020-02-28 Recombinant bacteria and uses thereof

Publications (1)

Publication Number Publication Date
SG11202109383XA true SG11202109383XA (en) 2021-09-29

Family

ID=72240222

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201901828TA SG10201901828TA (en) 2019-02-28 2019-02-28 Recombinant bacteria and uses thereof
SG11202109383XA SG11202109383XA (en) 2019-02-28 2020-02-28 Recombinant bacteria and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201901828TA SG10201901828TA (en) 2019-02-28 2019-02-28 Recombinant bacteria and uses thereof

Country Status (7)

Country Link
US (1) US20220133817A1 (en)
EP (1) EP3930736A4 (en)
JP (1) JP2022522295A (en)
CN (1) CN113660940A (en)
AU (1) AU2020229628A1 (en)
SG (2) SG10201901828TA (en)
WO (1) WO2020176042A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE226637T1 (en) * 1996-09-06 2002-11-15 Bioteknologisk Inst LACTIC ACID BACTERIAL ADJUSTABLE EXPRESSION SYSTEM
WO2002015928A1 (en) * 2000-08-18 2002-02-28 Medimmune, Inc. METHOD OF ADMINISTERING FimH PROTEIN AS A VACCINE FOR URINARY TRACT INFECTIONS
US9598697B2 (en) * 2010-05-28 2017-03-21 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
CA2955366A1 (en) * 2014-07-18 2016-01-21 Advaxis, Inc. Recombinant listeria strain expressing heterologous antigen fusion proteins and methods of use thereof

Also Published As

Publication number Publication date
US20220133817A1 (en) 2022-05-05
CN113660940A (en) 2021-11-16
JP2022522295A (en) 2022-04-15
EP3930736A4 (en) 2022-11-30
EP3930736A1 (en) 2022-01-05
WO2020176042A1 (en) 2020-09-03
SG10201901828TA (en) 2020-09-29
AU2020229628A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
EP3750548A4 (en) Lipopolysaccharide-regulated enteric bacteria and use thereof
IL268593A (en) Polypeptide variants and uses thereof
IL287781A (en) Clec12a-binding polypeptides and uses thereof
IL281171A (en) Cellulose-synthase-like enzymes and uses thereof
GB201620658D0 (en) Recombinant yeast and use thereof
IL290414A (en) Atf5 peptide variants and uses thereof
AU2018261021B2 (en) Recombinant modified fibroblast growth factors and therapeutic uses thereof
IL283418A (en) Christensenellaceae bacteria including christensenella minuta and uses thereof
IL287782A (en) Cd33-binding polypeptides and uses thereof
EP3723771A4 (en) Recombinant adenoviruses and uses thereof
EP4064862A4 (en) Designed bacterial compositions and uses thereof
GB2600592B (en) Polypeptide and use thereof
GB201819200D0 (en) Polypeptide and uses thereof
SG11202006669RA (en) Peptides and uses thereof
GB201901166D0 (en) Genetic construct and uses thereof
EP3816186A4 (en) Pd-l1-binding polypeptide and use thereof
ZA202104244B (en) Recombinant viruses and the uses thereof
GB2603645B (en) Polypeptides having anti-senescent effects and uses thereof
EP3947418C0 (en) Peptides and use thereof
SG11202111462VA (en) Asx-specific protein ligases and uses thereof
IL289531A (en) Cd38-binding agents and uses thereof
IL288828A (en) Cd38-binding agents and uses thereof
SG11202109383XA (en) Recombinant bacteria and uses thereof
GB201906914D0 (en) Substituted naphtahlene diimdes and their use
EP3576767A4 (en) Recombinant proteins and uses thereof